Search Results

You are looking at 61 - 70 of 1,111 items for :

  • "breast cancer" x
  • Refine by Access: All x
Clear All
Full access

Shi-Yi Wang, Tiange Chen, Weixiong Dang, Sarah S. Mougalian, Suzanne B. Evans, and Cary P. Gross

have reported that ODX is cost-effective for all women with ER-positive, node-negative breast cancer. 8 – 13 However, several important methodologic limitations may have diminished the accuracy of previous cost-effectiveness analyses (CEAs). 14 First

Full access

Rodrigo Goncalves and Ron Bose

clinically for early-stage breast cancer to predict recurrence risk and guide adjuvant chemotherapy decisions. Discuss the role of genome sequencing in breast cancer. Breast cancer is a heterogeneous disease with a wide range of outcomes that are not

Full access

Rowan T. Chlebowski, Aaron K. Aragaki, and Garnet L. Anderson

beginning in 1975, 2 , 3 the addition of progestin to reduce this risk became standard for women with an intact uterus. Shortly thereafter in 1976, the identification of an increased breast cancer risk associated with menopausal hormone therapy also raised

Full access

Jennifer A. Ligibel and Eric P. Winer

References 1 Group EBTC . Tamoxifen for early breast cancer: an overview of the randomized trials . Lancet 1998 ; 351 : 1451 – 1467 . 2 Report from the Breast Cancer Trials Committee SCTO, Edinburgh . Adjuvant tamoxifen

Full access

Robert W. Carlson, Clifford A. Hudis, and Kathy I. Pritchard

early breast cancer . Oncology (Williston Park) 2005 ; 19 : 1425 – 1428 , 1433 . 2. Osborne CK . Tamoxifen in the treatment of breast cancer . N Engl J Med 1998 ; 339 : 1609 – 1618 . 3. Field MJ Lohr KN , eds. Clinical

Full access

Sarah Asad, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce Niland, Antonio C. Wolff, Michael J. Hassett, and Daniel G. Stover

Background Triple-negative breast cancer (TNBC) is defined by a lack of targetable estrogen receptor (ER), progesterone receptor (PR), and HER2. TNBC accounts for a disproportionate amount of poor outcomes among patients with breast cancer

Full access

Cynthia Villarreal-Garza, Fernanda Mesa-Chavez, Alejandra Plata de la Mora, Melina Miaja-Avila, Marisol Garcia-Garcia, Alan Fonseca, Sylvia de la Rosa-Pacheco, Marlid Cruz-Ramos, Manuel Rolando García Garza, Alejandro Mohar, and Enrique Bargallo-Rocha

Background Breast cancer is the most commonly diagnosed malignancy among women of childbearing age. 1 In developed countries, approximately 7% of breast cancer cases are diagnosed in young women, 2 whereas in less thriving settings such as

Full access

Lee S. Schwartzberg and Sarah L. Blair

Undertreatment of Early-Stage Breast Cancer in Older Women Many elderly women (aged ≥65 years) with early-stage breast cancer are candidates for standard treatments, yet they often do not receive them, according to 2 members of the NCCN

Full access

Jill R. Tichy, Elgene Lim, and Carey K. Anders

, efforts to provide more comprehensive care to this distinct population continue. Evidence suggests that breast cancer in AYAs may be clinically and etiologically distinct from breast cancer in older women. 3 When breast cancer occurs in AYAs, it has a

Full access

Komal Jhaveri and Francisco J. Esteva

trastuzumab resulting in enhanced blockade of the HER signaling pathway Evaluate the safety and efficacy of pertuzumab in the management of HER2 + breast cancer in the neoadjuvant and metastatic settings Background Approximately 20% of breast